Systematic analysis of the relationship between intestinal microbiota and neurological disorders: emerging perspective in neurogastroenterology
DOI:
https://doi.org/10.51798/sijis.v5i2.758Keywords:
Microbiota, neurological disorders, neurogastroenterologyAbstract
By the complex gut-brain axis, the gut microbiota (GM) has a critical role in neurological function. The complex link between several neurological illnesses and the gut microbiota (GM) is examined in this comprehensive study. Strong evidence has been found, based on a review of the literature from 2019 to 2024, connecting GM dysbiosis to the etiology and development of conditions such as epilepsy, multiple sclerosis, Alzheimer's disease, autism spectrum disorder, stroke, and amyotrophic lateral sclerosis (ALS). In these cases, GM changes increase disease severity, interfere with immune responses, and worsen neuroinflammation. In particular, dysbiosis affects the prevalence of autoimmune encephalomyelitis in MS and adds to motor impairment and gastrointestinal symptoms in PD. Via pro-inflammatory microorganisms, dysregulated GM in AD exacerbates neurodegeneration. Moreover, the gut-brain axis influences emotion, behavior, and cognition, all of which are impacted by the development of ASD. In epilepsy, GM dysbiosis affects inflammatory responses and seizure frequency; in ALS, it leads to neuroinflammation and motor neuron degeneration. Notwithstanding noteworthy discoveries, the dearth of randomized controlled trials presents obstacles, requiring more mechanistic clarification and investigation of microbiota-targeted treatments for neurological disorders.
References
Arulsamy, Alina et al. 2020. “Gut Microbiota and Epilepsy: A Systematic Review on Their Relationship and Possible Therapeutics.” ACS Chemical Neuroscience 11(21): 3488–98. https://pubs.acs.org/doi/abs/10.1021/acschemneuro.0c00431 (February 29, 2024).
Bairamian, Diane et al. 2022. “Microbiota in Neuroinflammation and Synaptic Dysfunction: A Focus on Alzheimer’s Disease.” Molecular Neurodegeneration 17(1).
Balan, Yuvaraj et al. 2021. “Is the Gut Microbiota a Neglected Aspect of Gut and Brain Disorders?” Cureus.
Barichella, Michela et al. 2019. “Unraveling Gut Microbiota in Parkinson’s Disease and Atypical Parkinsonism.” Movement Disorders 34(3): 396–405.
Bhattarai, Yogesh et al. 2021. “Role of Gut Microbiota in Regulating Gastrointestinal Dysfunction and Motor Symptoms in a Mouse Model of Parkinson’s Disease.” Gut Microbes 13(1).
Blacher, Eran et al. 2019. “Potential Roles of Gut Microbiome and Metabolites in Modulating ALS in Mice.” Nature 572(7770): 474–80.
Blaser, Martin J. 2017. “The Theory of Disappearing Microbiota and the Epidemics of Chronic Diseases.” Nature Reviews Immunology 17(8): 461–63.
Boertien, Jeffrey M., Pedro A.B. Pereira, Velma T.E. Aho, and Filip Scheperjans. 2019. “Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson’s Disease: A Systematic Review.” Journal of Parkinson’s Disease 9(s2): S297–312.
Chen, Honglei et al. 2015. “Meta-Analyses on Prevalence of Selected Parkinson’s Nonmotor Symptoms before and after Diagnosis.” Translational Neurodegeneration 4(1).
Chen, Jun et al. 2016. “Multiple Sclerosis Patients Have a Distinct Gut Microbiota Compared to Healthy Controls.” Scientific Reports 6.
Cho, Ilseung, and Martin J. Blaser. 2012. “The Human Microbiome: At the Interface of Health and Disease.” Nature Reviews Genetics 13(4): 260–70.
Collins, Stephen M., Michael Surette, and Premysl Bercik. 2012. “The Interplay between the Intestinal Microbiota and the Brain.” Nature Reviews Microbiology 10(11): 735–42.
Cryan, John F. et al. 2019. “The Microbiota-Gut-Brain Axis.” Physiological Reviews 99(4): 1877–2013.
Dahlin, Maria, and Stefanie Prast-Nielsen. 2019. “The Gut Microbiome and Epilepsy.” EBioMedicine 44: 741–46. http://www.thelancet.com/article/S2352396419303251/fulltext (February 29, 2024).
Deidda, Gabriele, and Manuele Biazzo. 2021. “Gut and Brain: Investigating Physiological and Pathological Interactions Between Microbiota and Brain to Gain New Therapeutic Avenues for Brain Diseases.” Frontiers in Neuroscience 15.
Dominy, Stephen S. et al. 2019. “Porphyromonas Gingivalis in Alzheimer’s Disease Brains: Evidence for Disease Causation and Treatment with Small-Molecule Inhibitors.” Science Advances 5(1).
Felice, Valeria D., and Siobhain M. O’Mahony. 2017. “The Microbiome and Disorders of the Central Nervous System.” Pharmacology Biochemistry and Behavior 160: 1–13.
Fülöp, Tamàs et al. 2018. “Role of Microbes in the Development of Alzheimer’s Disease: State of the Art - An International Symposium Presented at the 2017 IAGG Congress in San Francisco.” Frontiers in Genetics 9(SEP).
Di Gioia, Diana et al. 2020. “A Prospective Longitudinal Study on the Microbiota Composition in Amyotrophic Lateral Sclerosis.” BMC Medicine 18(1): 1–19. https://link.springer.com/articles/10.1186/s12916-020-01607-9 (February 29, 2024).
Grochowska, Marta, Tomasz Laskus, and Marek Radkowski. 2019. “Gut Microbiota in Neurological Disorders.” Archivum Immunologiae et Therapiae Experimentalis 67(6): 375–83.
Haran, John P. et al. 2019. “Alzheimer’s Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway.” mBio 10(3).
Heinzel, Sebastian et al. 2021. “Retraction to: Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease (Annals of Neurology, (2020), 88, 2, (320-331), 10.1002/Ana.26151).” Annals of Neurology 90(3): E1–12.
Hills, Ronald D. et al. 2019. “Gut Microbiome: Profound Implications for Diet and Disease.” Nutrients 11(7).
Jin, Jinghua et al. 2023. “Gut-Derived β-Amyloid: Likely a Centerpiece of the Gut–Brain Axis Contributing to Alzheimer’s Pathogenesis.” Gut Microbes 15(1).
Keshavarzian, Ali et al. 2015. “Colonic Bacterial Composition in Parkinson’s Disease.” Movement Disorders 30(10): 1351–60.
Kras, Katarzyna et al. 2022. “Morphology and Chemical Coding of Rat Duodenal Enteric Neurons Following Prenatal Exposure to Fumonisins.” Animals 12(9).
Ma, Qianquan et al. 2019. “Impact of Microbiota on Central Nervous System and Neurological Diseases: The Gut-Brain Axis.” Journal of Neuroinflammation 16(1).
McCombe, Pamela A. et al. 2019. “Gut Microbiota in ALS: Possible Role in Pathogenesis?” Expert Review of Neurotherapeutics 19(9): 785–805. https://www.tandfonline.com/doi/abs/10.1080/14737175.2019.1623026 (February 29, 2024).
Mehra, Anshula et al. 2023. “Gut Microbiota and Autism Spectrum Disorder: From Pathogenesis to Potential Therapeutic Perspectives.” Journal of Traditional and Complementary Medicine 13(2): 135–49.
Mehra, Surabhi, Shruti Sahay, and Samir K. Maji. 2019. “α-Synuclein Misfolding and Aggregation: Implications in Parkinson’s Disease Pathogenesis.” Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1867(10): 890–908.
Mestre, Leyre et al. 2019. “Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis.” Frontiers in Immunology 10(JUN): 1–18.
Meyer, Katie et al. 2022. “Association of the Gut Microbiota with Cognitive Function in Midlife.” JAMA Network Open.
Nabi, Showkat Ul et al. 2022. “Mechanisms of Mitochondrial Malfunction in Alzheimer’s Disease: New Therapeutic Hope.” Oxidative Medicine and Cellular Longevity 2022.
Navas Llanos, S. T. ., & Guzmán Variña, C. B. (2023). Risk factors for Microtia and preventive approaches. Sapienza: International Journal of Interdisciplinary Studies, 4(SI1), e23046. https://doi.org/10.51798/sijis.v4iSI1.707
Naomi, Ruth et al. 2022. “Probiotics for Alzheimer’s Disease: A Systematic Review.” Nutrients 14(1).
Qian, Yiwei et al. 2018. “Alteration of the Fecal Microbiota in Chinese Patients with Parkinson’s Disease.” Brain, Behavior, and Immunity 70: 194–202.
Ramirez-Celis, Alexandra et al. 2021. “Risk Assessment Analysis for Maternal Autoantibody-Related Autism (MAR-ASD): A Subtype of Autism.” Molecular Psychiatry 2021 26:5 26(5): 1551–60. https://www.nature.com/articles/s41380-020-00998-8 (February 29, 2024).
Saurman, Virginia, Kara G. Margolis, and Ruth Ann Luna. 2020. “Autism Spectrum Disorder as a Brain-Gut-Microbiome Axis Disorder.” Digestive Diseases and Sciences 65(3): 818–28. https://link.springer.com/article/10.1007/s10620-020-06133-5 (February 29, 2024).
Shen, Heping et al. 2020. “New Mechanism of Neuroinflammation in Alzheimer’s Disease: The Activation of NLRP3 Inflammasome Mediated by Gut Microbiota.” Progress in Neuro-Psychopharmacology and Biological Psychiatry 100.
Suganya, Kanmani, and Byung Soo Koo. 2020. “Gut–Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions.” International Journal of Molecular Sciences 21(20): 1–29.
Thursby, Elizabeth, and Nathalie Juge. 2017. “Introduction to the Human Gut Microbiota.” Biochemical Journal 474(11): 1823–36.
Tiwari, Prabhakar et al. 2023. “Role of Gut Microbiota in Neurological Disorders and Its Therapeutic Significance.” Journal of Clinical Medicine 12(4). /pmc/articles/PMC9965848/ (February 28, 2024).
Ullah, Hanif et al. 2023. “The Gut Microbiota–Brain Axis in Neurological Disorder.” Frontiers in Neuroscience 17: 1225875.
Yano, Jessica M. et al. 2015. “Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis.” Cell 161(2): 264–76.
Zeng, Qianqian et al. 2020. “The Alteration of Gut Microbiome and Metabolism in Amyotrophic Lateral Sclerosis Patients.” Scientific Reports 2020 10:1 10(1): 1–12. https://www.nature.com/articles/s41598-020-69845-8 (February 29, 2024).
Zeraati, Maryam et al. 2019. “Gut Microbiota Depletion from Early Adolescence Alters Adult Immunological and Neurobehavioral Responses in a Mouse Model of Multiple Sclerosis.” Neuropharmacology 157: 107685.
Zhai, Chao Di et al. 2019. “Intestinal Microbiota Composition in Patients with Amyotrophic Lateral Sclerosis: Establishment of Bacterial and Archaeal Communities Analyses.” Chinese Medical Journal 132(15): 1815–22.
Zhang, Linhai et al. 2022. “Gut Microbes Regulate Innate Immunity and Epilepsy.” Frontiers in Neuroscience 16: 870197.
Zhu, Manlian et al. 2022. “Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease.” Frontiers in Immunology 13(June): 1–19.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jesus Alexander Cedeño Borrero, Jessica Valeria Medrano Aulestia, Arianna Cedeño Espinoza, Nathaly Marie Yepez Alcivar, Rommel Gustavo Vásconez Mora, Fanny Leonor Parrales Abarca
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
